Overall, these results and previous observations suggest that pharmacological inhibition of Chk1 could represent a novel and efficient therapeutic strategy not only for DLBCL with Myc overexpresssion, but also for other malignant B-cell lymphomas characterized by high Myc levels and high degree of genomic instability, like mantle cell lymphomas, even in cases with inactive p53. This evidence concerns the gene CHEK1 and B-cell non-Hodgkin lymphoma.